WO2019129174A1

WO2019129174A1 - Car-t cell targeting cd19 and expressing cd40 antibody at high level of stability, and use thereof

Info

Publication number: WO2019129174A1
Application number: PCT/CN2018/124680
Authority: WO
Inventors: 钱其军; 金华君; 唐熙; 何周; 刘祥箴; 李林芳; 崔连振
Original assignee: 上海细胞治疗研究院; 上海细胞治疗集团有限公司
Priority date: 2017-12-28
Filing date: 2018-12-28
Publication date: 2019-07-04
Also published as: CN109971722B; CN109971722A

Abstract

A CAR-T cell that targets CD19 and that expresses a CD40 antibody at a high level of stability, and a use thereof. The CAR-T cell contains a coding sequence for a chimeric antigen receptor that recognizes CD19 and a coding sequence for a CD40 activation antibody; and/or a chimeric antigen receptor that expresses and recognizes CD19 and a CD40 activation antibody. After the antibody and the CD40 antigen are combined, a costimulatory signal may be launched, promoting the activation and proliferation of CAR-T cells in vivo, and increasing the anti-tumor killing effect of cytotoxic T cells, thereby improving the efficacy of specifically killing tumors.

Description

CAR-T cells targeting CD19 and stably expressing CD40 antibodies at high levels and uses thereof

Technical field

The present invention pertains to genetic engineering and immunology, and relates to CAR-T cells that target CD19 and stably express CD40 antibodies at high levels and uses thereof.

Background technique

Tumor immunotherapy is one of the most promising research directions in the field of cancer treatment. "Science" magazine ranked tumor immunotherapy as the top ten scientific breakthroughs in 2013. There are many types of tumor immunotherapy. To date, the most popular immunotherapy with the best efficacy and the most potential to overcome tumor TB is chimeric antigen receptor T cells (CAR-T). Novartis's Kymriah and Kite's Yescarta two CAR-T products have been approved for marketing.

The chimeric antigen receptor (CAR) is a synthetic receptor that typically comprises an extracellular antigen binding domain, a transmembrane hinge region, and an intracellular signal transduction region. By using the antibody single-chain variable region (scFv) and the intracellular signal domain "immunoreceptor tyrosine-based activation motifs (ITAM)" that recognize the tumor associated antigen (TAA) The gene is recombined in vitro to generate a recombinant plasmid. This plasmid is then transferred into T cells by gene transduction, such that the genetically engineered T cells are referred to as CAR-T cells. After extensive expansion in vitro, CAR-T cells are returned to the patient and can exhibit potent anticancer effects in a non-MHC-restricted mode.

Malignant lymphoma is divided into two categories: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Hodgkin's lymphoma accounts for 10%-15% of lymphoma, while Hodgkin's lymphoma is the fastest-growing malignancy in patients with onset. According to WHO statistics, there are currently about 350,000 new NHLs in the world each year, and the death toll exceeds 200,000. B-cell lymphoma can be seen in both the Hodgkin's lymphoma and the non-Hodgkin's lymphoma. Currently, clinical treatments for lymphoma include cytotoxic drugs such as glucocorticoids and alkylating agents, and targeted drugs based on specific molecular targets (such as rituximab, etc.), wherein combination chemotherapy based on targeted drugs significantly improves partial lymphoma. Clinical remission rate and cure rate of patients. However, there are still a large number of patients with lymphoma who are not sensitive or have poor efficacy and are “real” refractory patients. Some new treatments (such as cellular immunotherapy) have relieved and prolonged survival in patients with partially relapsed or refractory lymphoma. There are many types of CAR-Ts currently being developed for hematological malignancies, including the use of anti-CD19, anti-CD20, anti-Kappa light chain, anti-CD22, anti-CD23, anti-CD30, anti-CD70 and other antibodies to construct CAR-modified T cells. Anti-tumor studies were conducted in which anti-CD19 and anti-CD20 monoclonal antibodies were the most popular.

Choosing the right tumor antigen as a target is the key to designing a safe and effective CAR-T. Since CD19 is expressed only in normal and malignant B cells at various stages of differentiation and not on other non-B cells (such as hematopoietic stem cells), it is a potential target for the treatment of B-lineage tumors and a hot spot in CAR-T research. Thus, CD19CAR-T is widely used for malignancy such as acute B lymphocytic leukemia (B-ALL), chronic B lymphocytic leukemia (B-CLL), mantle cell lymphoma (MCL), NHL, and multiple myeloma (MM). Clinical trial of B cell lymphoma.

CD40 antigen is a cell surface molecule belonging to the TNFR superfamily. It is a type I transmembrane glycoprotein with a molecular weight of 48KD and is widely expressed in T cells, antigen presenting cells, hematopoietic cells, granulocytes and the like. CD40L is a type II transmembrane glycoprotein belonging to the TNF superfamily and mainly expressed in CD4+ helper T cells (Th cells). CD40-CD40L is a pair of extremely important costimulatory molecules in the immune response with a wide range of biological effects. The CD40-CD40L interaction transmits signals, which up-regulates IL-12 levels, activates DC cells, enhances the ability of APC to present antigens, and CD40-CD40L also promotes the secretion of a large number of cytokines by T cells, such as GM-CSF, IL. -4, TNF-a, IFN-γ, thereby enhancing the CTL effect of CD8+ T cells and enhancing the killing effect on tumors. Researchers at the University of Huddersfield have developed a method of targeted therapy using CD40, which uses CD40 ligands to activate them and then target them by intravenous injection. The University of Huddersfield has patented the method (Oncogene, 2017 May 4; 36(18): 2515-2528). APX005M (NCT02482168) developed by Apexigen, a US biopharmaceutical research and development company, has good inhibitory effects on non-small cell carcinoma, melanoma, urothelial carcinoma, high frequency microsatellite instability (MSI-H), head and neck cancer.

Summary of the invention

The present invention provides a T cell that self-expresses a CD40 activating antibody and targets CD19.

In one or more embodiments, the expression cassette of the CD40 activating antibody and the expression cassette of the chimeric antigen receptor recognizing CD19 are integrated into the genome of the T cell.

In one or more embodiments, the amino acid sequence of the CD40 activating antibody is set forth in amino acid residues 21 to 497 of SEQ ID NO: 2, or as set forth in SEQ ID NO: 2.

In one or more embodiments, the coding sequence of the CD40 activating antibody is set forth in the base sequence of positions 61-1491 of SEQ ID NO: 4, or as set forth in SEQ ID NO: 4.

In one or more embodiments, the chimeric antigen receptor recognizing CD19, in sequence, comprises an optional signal peptide, an anti-CD19 single chain antibody, a hinge region, a transmembrane region, intracellular costimulation from N-terminus to C-terminus. Signal domain and intracellular signal domain.

In one or more embodiments, the signal peptide is a CD8 signal peptide, a CD28 signal peptide, a CD4 signal peptide or a light chain signal peptide; more preferably a CD8 signal peptide; preferably, the amino acid sequence of the CD8 signal peptide Shown as amino acid residues 1 to 21 of SEQ ID NO: 1.

In one or more embodiments, the amino acid sequence of the scFv is as shown in amino acid residues 22-263 of SEQ ID NO: 1.

In one or more embodiments, the hinge region is selected from the group consisting of the extracellular hinge region of CD8, the IgG1 Fc CH2CH3 hinge region, the IgD hinge region, the extracellular hinge region of CD28, the IgG4 Fc CH2CH3 hinge region, and the extracellular hinge of CD4. a region; preferably a CD8 alpha hinge region or an IgG4 CH2CH3 hinge region; preferably, the amino acid sequence of the CD8 alpha hinge region is as shown in amino acid residues 274-308 of SEQ ID NO: 1.

In one or more embodiments, the transmembrane region is a CD28 transmembrane region, a CD8 transmembrane region, a CD3ζ transmembrane region, a CD134 transmembrane region, a CD137 transmembrane region, an ICOS transmembrane region, and a DAP10 transmembrane region. One; preferably a CD8 transmembrane region, preferably having an amino acid sequence as shown in amino acid residues 309-332 of SEQ ID NO: 1.

In one or more embodiments, the intracellular costimulatory signal domain comprises an intracellular domain of a costimulatory signaling molecule, including CD28, CD134/OX40, CD137/4-1BB, lymphocyte-specific protein tyrosine kinase An intracellular domain of an inducible T cell costimulatory factor (ICOS) and DNAX activator protein 10; preferably, the intracellular costimulatory signal domain is an intracellular domain of CD137/4-1BB; preferably, said The amino acid sequence of CD137/4-1BB is shown as amino acid residues 333-374 of SEQ ID NO: 1.

In one or more embodiments, the intracellular signal domain is a CD3 sputum intracellular signal domain or an FcεRI gamma intracellular signal domain; preferably a CD3 sputum intracellular signal domain, preferably the amino acid sequence of the CD3 sputum intracellular signal domain is SEQ. ID NO: 1 shows the amino acid residues at positions 375-486.

In one or more embodiments, the amino acid sequence of the chimeric antigen receptor is as shown in amino acid residues 22 to 486 of SEQ ID NO: 1, or as shown in SEQ ID NO: 1; preferably, The coding sequence of the chimeric antigen receptor is shown as bases 64-1 to 458 of SEQ ID NO: 3, or as shown in SEQ ID NO: 3.

The invention also provides a composition comprising: a vector comprising an expression cassette of a chimeric antigen receptor of the invention, the vector for integrating the expression cassette into the genome of a host cell; A vector comprising an expression cassette for a CD40 activating antibody, the vector being used to integrate the expression cassette into the genome of a host cell.

The invention also provides a kit, the kit comprising:

(1) a vector comprising an expression cassette of a chimeric antigen receptor of the present invention, which vector is used to integrate the expression cassette into the genome of a host cell;

(2) A vector comprising an expression cassette of a CD40 activating antibody, which vector is used to integrate the expression cassette into the genome of a host cell.

The present invention also provides a pharmaceutical composition comprising the T cell of the present invention.

The invention also provides the use of a T cell as described herein in the manufacture of a medicament for the treatment or prevention of a malignancy. Preferably, the malignant tumor is a malignant B cell lymphoma, including acute B lymphocytic leukemia (B-ALL), chronic B lymphocytic leukemia (B-CLL), mantle cell lymphoma (MCL), NHL and multiple bone marrow Tumor (MM).

DRAWINGS

Figure 1: Schematic diagram of the gene structure of pNB328-CD19CAR, pS328-αCD40-wt, pS328-αCD40, pNB328-CD19CAR-2A-αCD40, pNB328-αCD40-IRES-CD19CAR.

Figure 2A: Positive rates of three CAR-T cells, CD19CAR-2A-αCD40, αCD40-IRES-CD19CAR, and CD19CAR-αCD40, constructed by different methods.

Figure 2B: CD19CAR-2A-αCD40, αCD40-IRES-CD19CAR, CD19CAR-αCD40 three CAR-T cell positive rate antibody secretion levels constructed by different methods.

3A-3B: Comparison of CD19CAR-αCD40T cell positive rate and antibody secretion amount constructed under different conditions of CAR and CD40 antibody plasmid.

Figure 4: Comparison of CD19CAR-secretion levels IL-2, IL-4, IL-6, IL-10, TNF-, and IFN-, cytokine secretion changes under CD19 antigen stimulation.

Figure 5: Proliferation assay of CD19CAR T cells and CD19 CAR-αCD40 T cells.

Figure 6: Therapeutic effect of CD19CAR T cells, CD19CAR-αCD40-wt T, CD19CAR-αCD40T cells on a mouse Raji-luc xenograft model.

Detailed ways

Some of the terms related to the present invention are explained below.

In the present invention, the term "expression cassette" refers to an entire element required for expression of a gene, including a promoter, a gene coding sequence, and a transcription terminator sequence such as (PolyA tailing signal sequence).

The term "coding sequence" is defined herein as a portion of a nucleic acid sequence that directly determines the amino acid sequence of its protein product (eg, CAR, single chain antibody, hinge region, and transmembrane region). The boundaries of the coding sequence are typically determined by a ribosome binding site (for prokaryotic cells) immediately upstream of the open reading frame of the 5' end of the mRNA and a transcription termination sequence immediately downstream of the open reading frame of the 3' end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.

The term "Fc", ie, fragment crystallizable (Fc) of an antibody, refers to a peptide located at the end of the handle of the "Y" structure of the antibody molecule, comprising the CH2 and CH3 domains of the heavy chain constant region of the antibody, and is an antibody and effect. The site of molecular or cellular interactions.

The term "costimulatory molecule" refers to a molecule that is present on the surface of an antigen presenting cell and that binds to a costimulatory molecule receptor on a Th cell to produce a costimulatory signal. The proliferation of lymphocytes requires not only the binding of antigens, but also the signals of costimulatory molecules. The costimulatory signal is transmitted to the T cells mainly by binding to the co-stimulatory molecule CD80 on the surface of the antigen presenting cells, and CD86 binds to the CD28 molecule on the surface of the T cell. B cells receive a costimulatory signal that can pass through a common pathogen component such as LPS, or through a complement component, or through activated antigen-specific Th cell surface CD40L.

The term "linker" or hinge is a polypeptide fragment that links between different proteins or polypeptides for the purpose of maintaining the spatial conformation of the linked protein or polypeptide to maintain the function or activity of the protein or polypeptide. Exemplary linkers include linkers containing G and/or S, as well as, for example, Furin 2A peptide.

The term "specifically binds" refers to the reaction between an antibody or antigen-binding fragment and the antigen to which it is directed. In certain embodiments, an antibody that specifically binds to an antigen (or an antibody that is specific for an antigen) means that the antibody is less than about 10 ^-5 M, such as less than about 10 ^-6 M, 10 ^-7 M, Affinity (KD) of 10 ^-8 M, 10 ^-9 M or 10 ^-10 M or less binds to the antigen. "Specific recognition" has a similar meaning.

The term "pharmaceutically acceptable excipient" refers to carriers and/or excipients that are compatible pharmacologically and/or physiologically to the subject and active ingredient, which are well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers. For example, pH adjusting agents include, but are not limited to, phosphate buffers; surfactants include, but are not limited to, cationic, anionic or nonionic surfactants such as Tween-80; ionic strength enhancers include, but are not limited to, sodium chloride.

The term "effective amount" refers to a dose that can achieve a treatment, prevention, alleviation, and/or alleviation of a disease or condition described herein in a subject.

The term "disease and/or condition" refers to a physical state of the subject that is associated with the disease and/or condition described herein.

The term "subject" or "patient" may refer to a patient or other animal that receives the pharmaceutical composition of the invention to treat, prevent, ameliorate and/or alleviate the disease or condition of the invention, particularly a mammal, such as a human, a dog. , monkeys, cattle, horses, etc.

The term "chimeric antigen receptor" (CAR) is an artificially engineered receptor that anchors specific molecules (such as antibodies) that recognize tumor cell surface antigens to immune cells (such as T cells), allowing immune cells to recognize tumor antigens. Or viral antigens and cells that kill tumor cells or virus infection. CAR typically comprises, in turn, an optional signal peptide, a polypeptide that binds to a tumor cell membrane antigen, such as a single chain antibody, a hinge region, a transmembrane region, and an intracellular signaling region. Generally, a polypeptide that binds to a tumor cell membrane antigen is capable of binding to a membrane antigen that is widely expressed by tumor cells with moderate affinity. The polypeptide that binds to the tumor cell membrane antigen may be a natural polypeptide or a synthetic polypeptide; preferably, the synthetic polypeptide is a single chain antibody or a Fab fragment.

The term "single-chain antibody" (scFv) refers to an antibody fragment which is obtained by hinge-ligating an amino acid sequence of an antibody light chain variable region (VL region) and a heavy chain variable region (VH region), and having antigen-binding ability. In certain embodiments, the single chain antibody of interest (scFv) is from an antibody of interest. Antibodies of interest may be human antibodies, including human murine chimeric antibodies and humanized antibodies. The antibody may be secreted or membrane anchored; preferably a membrane anchored.

The inventors unexpectedly discovered during the research of CAR-T that the addition of CD40 antibody significantly improved the proliferation ability and killing ability of CAR-T. In view of the complicated production preparation and purification process involved in the production of CD40 monoclonal antibody, the cost is high, leading to treatment. The invention is expensive, and the present inventors express CD40 antibody on the existing CD19 CAR-T cells, and when combined with the CD40 antigen, can initiate the costimulatory signal, promote the activation and proliferation of CAR-T cells in vivo, and increase the anti-tumor of cytotoxic T cells. The killing effect, thereby improving the efficacy of specific killing of tumors.

Studies have shown that the IgG4 Fc fragment of CD40-activating antibody is easily phagocytosed by monocyte/macrophage recognition, and the CD40-activating antibody of the CD40-activated antibody IgG4Fc fragment of the present invention can be modified to meet the T-cell self-expression. It works well and does not cause ADCC reactions.

Accordingly, the present invention provides a CD40 activating antibody which up-regulates the levels of TNF-α, TRAIL and FasL, inhibits the growth of tumor cells, and promotes the proliferation efficiency of CAR-T cells by regulating cell cycle/proliferation. , prolonging the action time in the body, thereby enhancing the CAR-T effect in multiple aspects.

The CD40 activating antibody of the present invention contains an anti-CD40 single chain antibody and IgG4Fc. In certain embodiments, the amino acid sequence of the IgG4 Fc is set forth in amino acid residues 269-497 of SEQ ID NO: 2; preferably, the coding sequence thereof is set at bases 805-1491 of SEQ ID NO: Shown.

In certain embodiments, the antibody light chain variable region (VL region) amino acid sequence of the anti-CD40 single-chain antibody (scFv) is represented by amino acid residues 21 to 146 of SEQ ID NO: 2; preferably, Its coding sequence is shown in nucleotide sequence 64-438 of SEQ ID NO:4. In certain embodiments, the heavy chain variable region (VH region) amino acid sequence of the anti-CD40 single-chain antibody is set forth in amino acids at positions 161-168 of SEQ ID NO: 2; preferably, the coding sequence thereof is The nucleotide sequence at positions 481 to 804 of SEQ ID NO: 4 is shown. In certain embodiments, the amino acid sequence of the anti-CD40 single chain antibody is set forth as amino acid residues 21 to 268 of SEQ ID NO: 2; preferably, the coding sequence thereof is SEQ ID NO: 4, 61-804 The base sequence is shown.

In certain embodiments, the CD40 antibody further comprises a light chain signal peptide. In certain embodiments, the CD40 antibody comprises, from the N-terminus to the C-terminus, a light chain signal peptide, an anti-CD40 single chain antibody, and an IgG4 Fc in sequence. In certain embodiments, the amino acid sequence of the light chain signal peptide is represented by amino acid residues 1-20 of SEQ ID NO: 2; preferably, the coding sequence of the indicated light chain signal peptide is SEQ ID NO: 4 The base sequence of the 1-60th base is shown.

In certain embodiments, the amino acid sequence of the CD40 activating antibody is set forth in amino acid sequence 21-497 of SEQ ID NO: 2, or as set forth in SEQ ID NO: 2.

The invention also encompasses a coding sequence for the CD40 antibody or a complement thereof, the coding sequence comprising at least the coding sequence for an IgG4 Fc described herein or a complement thereof. In certain embodiments, the coding sequence of the CD40 antibody comprises the sequence set forth in bases 61-1491 of SEQ ID NO:4, preferably comprising the sequence set forth in SEQ ID NO:4.

The present invention also encompasses a nucleic acid construct comprising the coding sequence of a CD40 antibody of the present invention or a complement thereof. Preferably, the nucleic acid construct is an expression vector or an integration vector for integrating the coding sequence or its complement into a host cell.

The invention also provides a host cell comprising a nucleic acid construct as described herein.

The invention also provides the use of the CD40 antibody, its coding sequence or complementary sequence, a nucleic acid construct, and a host cell for the preparation or treatment of a malignant tumor, particularly a CD40-associated tumor, including but not limited to Various malignant tumors.

The present invention also provides a pluripotent T cell which is modified by the CD19CAR gene and can express a CD40 activating antibody, and the T cell can stably express the CD19CAR gene and the CD40 activating antibody at a high level, and the exogenously expressed CD19CAR gene can accurately target To CD19 antigen, enhance the proliferation of T cells and the secretion of cytokines, the expression of CD40-activating antibodies can help CAR-T cells to break through the inhibition of tumor microenvironment, thereby enhancing the killing of tumor cells by CAR-T cells, and by enhancing The immune response exerts an anti-tumor effect. At the same time, the exogenous CAR gene and the CD40 activating antibody gene can be integrated into the genome of the T cell via the PB transposase system, thereby stably and continuously expressing in the T cell. The high level of T cells stably expressing the CAR gene and the CD40 activating antibody gene obtained by the present invention can be used for the treatment of a variety of CD19-expressing malignant lymphomas.

The CAR of the invention typically contains an optional signal peptide sequence, an scFv that recognizes the CD19 antigen, a hinge region, a transmembrane region, an intracellular costimulatory signal domain, and an intracellular signal domain.

A signal peptide is a short peptide chain (5-30 amino acids in length) that directs the transfer of newly synthesized proteins to the secretory pathway, often referred to as the N-terminal amino acid sequence in the newly synthesized polypeptide chain that directs transmembrane transfer (localization) of the protein. (Sometimes not necessarily at the N-terminus), it is responsible for directing proteins into subcellular organelles with different membrane structures. The signal peptide can be a secreted signal peptide or a membrane-bound signal peptide. In certain embodiments, the signal peptide is a CD8 signal peptide, a CD28 signal peptide, or a CD4 signal peptide; more preferably a CD8 signal peptide. The amino acid sequence of the CD8 signal peptide can be as shown in amino acid residues 1-21 of SEQ ID NO: 1; in certain embodiments, the coding sequence is set forth in bases 1-63 of SEQ ID NO: 3.

The scFv recognizing the CD19 antigen may be a scFv that recognizes the CD19 antigen commonly used in the art. In certain embodiments, the amino acid sequence of the scFv is as shown in amino acid residues 22-263 of SEQ ID NO: 1; in certain embodiments, the coding sequence is SEQ ID NO: 3, pp. 64-789 The base is shown.

Herein, the hinge region refers to the region between the functional regions of the immunoglobulin heavy chain CH1 and CH2, which is rich in proline, does not form an alpha helix, is prone to stretching and is somewhat distorted, and is beneficial to the antigen binding site of the antibody. Complementary binding between epitopes. The hinge region suitable for use herein may be selected from any one or more of the extracellular hinge region of CD8, the IgG1 Fc CH2CH3 hinge region, the IgD hinge region, the extracellular hinge region of CD28, the IgG4 Fc CH2CH3 hinge region, and the extracellular hinge region of CD4. . The hinge region is preferably a hinge region that is longer than 50 amino acid residues, more preferably 80 amino acids or longer. In certain embodiments, a CD8 alpha hinge region or an IgG4 Fc CH2CH3 hinge region is used herein. The amino acid sequence of the exemplary CD8 alpha hinge region is shown in amino acid residues 264 to 308 of SEQ ID NO: 1, and the coding sequence thereof is shown in positions 790-924 of SEQ ID NO: 3.

The transmembrane region may be one of a CD28 transmembrane region, a CD8 transmembrane region, a CD3ζ transmembrane region, a CD134 transmembrane region, a CD137 transmembrane region, an ICOS transmembrane region, and a DAP10 transmembrane region; preferably a CD8 transmembrane region Preferably, the amino acid sequence thereof is represented by amino acid residues 309-332 of SEQ ID NO: 1; in certain embodiments, the coding sequence is set forth in bases 925-996 of SEQ ID NO: 10.

The intracellular co-stimulatory signal domain including the intracellular domain of the costimulatory signaling molecule may be selected from the group consisting of CD28, CD134/OX40, CD137/4-1BB, lymphocyte-specific protein tyrosine kinase (LCK), and inducible T cell costimulation. Intracellular domain of factor (ICOS) and DNAX activator protein 10 (DAP10). In certain embodiments, the intracellular domain of the costimulatory signaling molecule is the intracellular domain of CD137/4-1BB; preferably, the amino acid sequence of the CD137/4-1BB is SEQ ID NO: 1 Shown at amino acid residues 333-374; in certain embodiments, the coding sequence is set forth in bases 997-1122 of SEQ ID NO: 3.

The intracellular signal domain is preferably an immunoreceptor tyrosine activation motif, which may be a CD3 sputum intracellular signal domain or an FcεRI gamma intracellular signal domain; preferably a CD3 sputum intracellular signal domain, preferably the amino acid sequence of the CD3 sputum intracellular signal domain As described in amino acid residues 375-486 of SEQ ID NO: 1; in certain embodiments, the coding sequence is set forth in bases 1123-1458 of SEQ ID NO: 3.

In certain embodiments, the chimeric antigen receptor comprises, in order from the N-terminus to the C-terminus, an scFv, a CD8 hinge region, a CD8 transmembrane region, a 4-1BB and a CD3 intracellular signal domain; preferably, the inlay The amino acid sequence of the antigen receptor is shown as amino acid residues 22 to 486 of SEQ ID NO: 1. In certain embodiments, the chimeric antigen receptor further comprises a signal peptide, preferably, the amino acid sequence of the chimeric antigen receptor is as shown in amino acid residues 1-21 of SEQ ID NO: 1.

It will be understood that the invention also encompasses chimeric antibody receptors and coding sequences thereof as described herein.

Forming the above-described various portions of the chimeric antigen receptors herein, such as the signal peptide, the light chain variable region and the heavy chain variable region, the hinge region, the transmembrane region, the intracellular costimulatory signal domain, and the intracellular region of the anti-CD19 single chain antibody Signal domains, etc., can be directly connected to each other or can be connected by a linker sequence. The linker sequence can be a linker sequence suitable for use in antibodies well known in the art, such as linker sequences comprising G and S. The linker may be 3 to 25 amino acid residues in length, for example 3 to 15, 5 to 15, and 10 to 20 amino acid residues. In certain embodiments, the linker sequence is a polyglycine linker sequence. The amount of glycine in the linker sequence is not particularly limited, but is usually 2 to 20, for example, 2 to 15, 2 to 10, and 2 to 8. In addition to glycine and serine, the linker may also contain other known amino acid residues such as alanine (A), leucine (L), threonine (T), glutamic acid (E), styrene Amino acid (F), arginine (R), glutamine (Q), and the like.

It will be appreciated that in gene cloning procedures, it is often desirable to design a suitable cleavage site which necessarily introduces one or more irrelevant residues at the end of the expressed amino acid sequence without affecting the activity of the sequence of interest. In order to construct a fusion protein, promote expression of a recombinant protein, obtain a recombinant protein that is automatically secreted outside the host cell, or facilitate purification of the recombinant protein, it is often necessary to add some amino acids to the N-terminus, C-terminus of the recombinant protein or within the protein. Other suitable regions include, for example, but are not limited to, suitable linker peptides, signal peptides, leader peptides, terminal extensions, and the like. Thus, the amino or carboxy terminus of a CAR herein may also contain one or more polypeptide fragments as a protein tag. Any suitable label can be used in this article. For example, the tags may be FLAG, HA, HA1, c-Myc, Poly-His, Poly-Arg, Strep-TagII, AU1, EE, T7, 4A6, ε, B, gE and Ty1. These tags can be used to purify proteins.

Also included herein are polynucleotide sequences encoding the chimeric antigen receptor. The polynucleotide sequence herein may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA or synthetic DNA. DNA can be single-stranded or double-stranded.

The polynucleotide sequences described herein can generally be obtained by PCR amplification. In particular, primers can be designed according to the nucleotide sequences disclosed herein, and the relevant sequences can be amplified using a commercially available cDNA library or a cDNA library prepared by a conventional method known to those skilled in the art as a template. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then the amplified fragments are spliced together in the correct order. For example, in certain embodiments, the polynucleotide sequence encoding a fusion protein described herein is set forth in SEQ ID NO:3.

Also included herein are nucleic acid constructs comprising a polynucleotide sequence encoding the chimeric antigen receptor described herein or a polynucleotide sequence encoding the CD40 activating antibody, and one or operably linked to the sequences Multiple regulatory sequences. In certain embodiments, the nucleic acid constructs of the invention are expression cassettes.

The control sequence can be a suitable promoter sequence. The promoter sequence is typically operably linked to the coding sequence of the protein to be expressed. The promoter may be any nucleotide sequence that exhibits transcriptional activity in the host cell of choice, including mutated, truncated and hybrid promoters, and may be derived from an extracellular or heterologous source encoding the host cell. Or the gene of the intracellular polypeptide is obtained.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by the host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleotide sequence encoding the polypeptide. Any terminator that is functional in the host cell of choice may be used herein.

In certain embodiments, the nucleic acid construct is a vector. In particular, the coding sequences of the CARs herein or the coding sequences for CD40 activating antibodies can be cloned into many types of vectors, for example, but not limited to plasmids, phagemids, phage derivatives, animal viruses, and cosmids. . The vector can be an expression vector. The expression vector can be provided to the cells in the form of a viral vector. Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses.

Generally, suitable vectors comprise an origin of replication, a promoter sequence, a convenient restriction enzyme site, and one or more selectable markers that function in at least one organism. For example, in certain embodiments, the invention employs a retroviral vector containing a replication initiation site, a 3'LTR, a 5' LTR, a coding sequence for a CAR described herein, or a CD40 activating antibody A coding sequence, and optionally a selectable marker.

Suitable promoters include, but are not limited to, immediate early cytomegalovirus (CMV) promoter sequences. The promoter sequence is a strong constitutive promoter sequence capable of driving high level expression of any polynucleotide sequence operably linked thereto. Another example of a suitable promoter is Elongation Growth Factor-1 alpha (EF-1 alpha). However, other constitutive promoter sequences can also be used, including but not limited to human prion 40 (SV40) early promoter, mouse breast cancer virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, EB virus immediate early promoter, Russ sarcoma virus promoter, and human gene promoters such as, but not limited to, actin promoter, myosin promoter, heme Promoter and creatine kinase promoter. Further, an inducible promoter can also be considered. The use of an inducible promoter provides a molecular switch that is capable of opening expression of a polynucleotide sequence operably linked to an inducible promoter upon expression of the term, and shutting down expression when expression is undesirable. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.

In certain embodiments, various promoter sequences disclosed in CN201510021408.1 can be used, including but not limited to the CCEF promoter containing the mCMV enhancer, the hCMV enhancer, and the EF1α promoter shown in SEQ ID NO: 5 of the application. TCEF promoter containing CD3e enhancer, mCMV enhancer, hCMV enhancer and EF1α promoter as shown in SEQ ID NO: 7; mCMV-containing enhancer, hCMV enhancer and inclusion as shown in SEQ ID NO: a CCEFI promoter of the EF1α promoter containing a subunit; a TEFI promoter comprising a CD3e enhancer and an intron-containing EF1α promoter represented by SEQ ID NO: 3; and a CD3e enhancer represented by SEQ ID NO: , the mCMV enhancer, the hCMV enhancer, and the TCEFI promoter of the intron-containing EF1α promoter. The entire contents of this application are herein incorporated by reference.

The selectable marker includes either or both of the selectable marker genes or reporter genes to facilitate identification and selection of the expressed cells from the population of cells infected by the viral vector. Useful selectable marker genes include, for example, antibiotic resistance genes such as neo and the like. Suitable reporter genes may include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secreted alkaline phosphatase or green fluorescent protein genes.

In certain embodiments, the coding sequence of the chimeric antigen receptor described herein and the coding sequence of a CD40 activating antibody can be separately cloned into a vector for integration of the nucleic acid sequence of interest into the genome of the host cell (also referred to as In order to integrate vectors, in particular transposon vectors. In certain embodiments, the transposon vector is a eukaryotic expression vector comprising a transposable element selected from the group consisting of piggybac, sleeping beauty, frog prince, Tn5 or Ty. Such transposon vectors contain the 5' inverted terminal repeat (5' LTR) of the corresponding transposon and the 3' inverted terminal repeat (3' LTR) of the corresponding transposon. The transposase can be a transposase from a piggybac, sleeping beauty, frog prince, Tn5 or Ty transposition system. When a transposase from a different transposition system is used, the sequences of the 5'LTR and 3'LTR in the vector are also correspondingly changed to sequences adapted to the transposition system, which can be readily determined by those skilled in the art. . Between the 5' LTR and the 3' LTR is the expression cassette for the CAR or antibody of the invention, including the corresponding promoter sequence, the coding sequence for the CAR or antibody, and the transcription terminator sequence (e.g., the polyA tailing signal sequence).

In certain embodiments, the transposase is a transposase from a piggybac transposition system. Thus, in these embodiments, the 5' inverted terminal repeat and the 3' inverted terminal repeat of the transposon are the 5' inverted terminal repeat and the 3' inverted terminal repeat of the piggybac transposon, respectively. In certain embodiments, the transposon 5' inverted terminal repeat is SEQ ID NO: 1 as described in CN 201510638974.7, the disclosure of which is incorporated herein by reference. In certain embodiments, the transposon 3' inverted terminal repeat is as shown in CN 201510638974.7 SEQ ID NO: 4. In certain embodiments, the piggybac transposase is a transposase comprising a c-myc nuclear localization signal coding sequence. In certain embodiments, the coding sequence for the piggybac transposase is as shown in CN 201510638974.7 SEQ ID NO: 5.

The promoter of the transposase coding sequence can be a variety of promoters known in the art for controlling expression of the transposase coding sequence. In certain embodiments, the expression of the transposase coding sequence is controlled using a CMV promoter. The sequence of the CMV promoter can be as shown in CN 201510638974.7 SEQ ID NO: 6.

In certain embodiments, the vector of the present invention comprising a coding sequence for a chimeric antigen receptor is the pNB328 vector disclosed in CN 201510638974.7. The coding sequence of the chimeric antigen receptor of the present invention can be prepared by a method conventional in the art and cloned into a suitable vector.

In certain embodiments, the vector for integrating a gene of interest into the genome of a host cell does not contain a transposase coding sequence. For example, such vectors can be obtained by removing the transposase coding sequence based on the pNB328 vector. Typically, such vectors are used to integrate the coding sequence for a CD40 activating antibody and a signal peptide coding sequence (such as the coding sequence for a light chain signal peptide) into the genome of a host cell.

In certain embodiments, a T cell modified by a CD19 CAR gene and capable of expressing a CD40 activating antibody as described herein can be transduced into a transposase comprising a chimeric antigen receptor coding sequence for integration into the T cell genome. A vector encoding a sequence, and a vector comprising no transposase coding sequence for integration into the coding sequence of a CD40 activating antibody described herein in the T cell genome.

Preferably, the T cell is transformed into a vector containing a chimeric antigen receptor coding sequence constructed using the pNB328 vector as a backbone vector and constructed using a pS328 vector (with no transposase coding sequence compared to pNB328) as a backbone vector. A vector containing a CD40 activating antibody coding sequence. In certain embodiments, the coding sequence of the chimeric antigen receptor is set forth in the base sequence of SEQ ID NO: 3, positions 64-1458, or as set forth in SEQ ID NO: 3; the CD40 activating antibody The coding sequence is shown as the base sequence of positions 61-1491 of SEQ ID NO:4. In certain embodiments, in the vector comprising the coding sequence for a CD40 activating antibody, the signal peptide of the CD40 activating antibody is a light chain signal peptide. The amino acid sequence of an exemplary light chain signal peptide can be as shown in amino acid residues 1-20 of SEQ ID NO:2. More specifically, in certain embodiments, the vector comprising a transposase coding sequence that incorporates a chimeric antigen receptor coding sequence in a T cell genome comprises a 5' LTR, a promoter, a CD8 signal peptide coding sequence , coding sequence of scFv recognizing CD19 antigen, coding sequence of CD8 hinge region, coding sequence of CD8 transmembrane region, coding sequence of 4-1BB, coding sequence of CD3 intracellular signal domain, polyA tailing signal sequence, 3'LTR And a transposase coding sequence and a promoter sequence thereof; said vector comprising a transposase coding sequence encoding a coding sequence for a CD40 activating antibody as described herein in a T cell genome at 5'LTR and 3'LTR The coding sequence of the promoter, the light chain signal peptide, the coding sequence of the CD40 activating antibody, and the polyA tailing signal sequence are sequentially contained between them.

Preferably, at the time of transfection, the mass ratio of the vector containing the chimeric antigen receptor coding sequence to the vector containing the CD40 activating antibody coding sequence is from 1 to 7:1 to 7, preferably from 1 to 3:1 to 3, preferably 1 : 1 to 3, more preferably 1:1 to 2, still more preferably 1:1.

Methods of transfection are routine methods in the art including, but not limited to, viral transduction, microinjection, particle bombardment, gene gun transformation, and electroporation. In certain embodiments, the vector is transfected into a cell of interest using electroporation.

The cells of interest may be various T cells well known in the art including, but not limited to, peripheral blood T lymphocytes, cytotoxic killer T cells (CTLs), helper T cells, suppressor/regulatory T cells, γδ T cells, and cytokines. T cells of mixed cell populations such as induced killer cells (CIK) and tumor infiltrating lymphocytes (TIL).

The invention also provides a composition comprising a vector comprising an expression cassette for a chimeric antigen receptor described herein and a vector comprising an expression cassette for a CD40 activating antibody described herein. Suitable agents may also be included in the compositions including, but not limited to, transfection reagents.

The invention also provides a kit comprising a vector comprising an expression cassette for a chimeric antigen receptor described herein and a vector comprising an expression cassette for a CD40 activating antibody described herein, or a combination as described herein Things. A reagent or instrument for transferring the vector into a cell can also be provided in the kit.

As described herein, the expression cassette contains at least a suitable promoter and transcription terminator sequence (e.g., a polyA tail signal sequence) in addition to the coding sequence comprising a chimeric antigen receptor or a CD40 activating antibody.

The invention also provides a pharmaceutical composition comprising a T cell as described herein. Suitable pharmaceutically acceptable carriers or excipients may be included in the pharmaceutical compositions. The pharmaceutical composition contains a therapeutically or prophylactically effective amount of T cells. The therapeutically or prophylactically effective amount of the T cell can be determined according to factors such as the condition of the patient.

The invention also provides the use of a T cell or a pharmaceutical composition thereof as described herein for the manufacture of a medicament for the treatment or prevention of a malignancy.

The present invention also provides a method of treating or preventing a malignant tumor, which comprises administering to a subject in need thereof a therapeutically or prophylactically effective amount of a T cell of the present invention. Malignant tumors are malignant B-cell lymphomas, including acute B-lymphocytic leukemia (B-ALL), chronic B-lymphocytic leukemia (B-CLL), mantle cell lymphoma (MCL), NHL, and multiple myeloma (MM).

Embodiments of the present invention will be described in detail below with reference to the embodiments. Those skilled in the art will appreciate that the following examples are merely illustrative of the invention and are not to be considered as limiting the scope of the invention. In the examples, the specific techniques or conditions are not indicated, according to the techniques or conditions described in the literature in the field (for example, refer to J. Sambrook et al., Huang Peitang et al., Molecular Cloning Experimental Guide, Third Edition, Science Press) or in accordance with the product manual. The reagents or instruments used are not specified by the manufacturer, and are conventional products that can be purchased through the market.

Example 1: Construction of recombinant plasmids pNB328-CD19CAR, pS328-αCD40, pS328-αCD40-wt, pNB328-αCD40-IRES-CD19CAR, pNB328-CD19CAR-2A-αCD40 and acquisition of chimeric antigen receptor-modified T cells

Commissioned by Shanghai Jierui Biotech Co., Ltd. to synthesize CD19CAR (nucleotide sequence as shown in SEQ ID NO: 3, amino acid sequence as shown in SEQ ID NO: 1), anti-CD40 (αCD40) (sequence as shown in SEQ ID NO: 4) , amino acid sequence as shown in SEQ ID NO: 2), anti-CD40-wt (αCD40-wt) (nucleotide sequence shown in SEQ ID NO: 9, amino acid sequence shown in SEQ ID NO: 8), CD19CAR -2A-αCD40 (the nucleotide sequence of 2A is shown in SEQ ID NO: 5, the amino acid sequence is shown in SEQ ID NO: 6) and the αCD40-IRES-CD19CAR gene (the nucleotide sequence of IRES is SEQ ID NO: 7)), its structural pattern is shown in Figure 1, which was inserted between pNB328, pS328 vector EcoRI and SalI restriction sites, and the recombinant plasmids were named pNB328-CD19CAR, pS328-αCD40, pS328- αCD40-wt, pNB328-CD19CAR-2A-αCD40, pNB328-αCD40-IRES-CD19CAR.

The structure and sequence of pNB328 are described in CN 201510638974.7, the entire disclosure of which is hereby incorporated by reference in its entirety in its entirety in the in the in in in in in in in in in in in in in in in in in in in in in in in in in in The promoter sequence and the polyA tailing signal sequence are not shown in the respective structural pattern diagrams, which are located between the 5'LTR and the signal peptide sequence and before the 3' LTR, respectively.

Example 2: Construction of CAR T cells

Peripheral blood mononuclear cells (PBMCs) were isolated from the Shanghai Cell Therapy Production Center. The PBMCs were cultured for 2-4 h, and the unattached suspension cells were the initial T cells. The suspension cells were collected into 15 ml centrifuge tubes, centrifuged at 1200 rmp for 3 min, the supernatant was discarded, physiological saline was added, and centrifuged at 1200 rmp for 3 min to abandon the physiology. Saline, and repeat this step; take four 1.5ml centrifuge tubes, add 5 × 10 ⁶ cells per tube, number a, b, c, d, centrifuge at 1200rmp for 3min, discard the supernatant, and take the electrotransfer kit (from Lonza ), a, b, c, d tubes were added to the electrophoresis reagent in a total amount of 100 ul, a tube was added to the constructed recombinant plasmid pNB328-CD19CAR, pS328-αCD40 each 4ug, b tube was added to pNB328-CD19CAR-2A-αCD40 plasmid 6ug, c The tube was added with 6 ug of pNB328-αCD40-IRES-CD19CAR plasmid, and 6 ug of the control plasmid was added to the tube; the mixture was transferred to an electric rotor, placed in an electrorotator, and the desired procedure was selected for electric shock; the electrophoresis was carried out using a micropipette in the kit. Transfer the good cell suspension to a six-well plate (with 2% FBS AIM-V), mix well, place at 37 ° C, incubate in a 5% CO2 incubator, and add stimulating factor after 6 hours. IL-2 and CD19/anti-CD28, cultured at 37 ° C, 5% CO 2 for 3-4 days, observed T cells Long case, and obtained from the expression of CD40 antibody targeting the CD19 cell CD19CAR-αCD40T, CD19CAR-2A-αCD40T cells and αCD40-IRES-CD19CAR T cells.

Using the same method, CD19CAR T cells were constructed using pNB328-CD19CAR (6 ug) constructed in Example 1; Mock T cells were constructed using pNB328 blank plasmid (6 ug); pNB328-CD19CAR (4 ug) constructed using Example 1 was used. CD19CAR-αCD40-wt T cells were constructed with pS328-αCD40-wt (4 ug).

Example 3: CAR T cell positive rate and antibody secretion targeting CD19 from CD40 antibody-expressing

1. Flow detection of CAR T cell positive rate

The CD19CAR-αCD40T cells, CD19CAR-2A-αCD40T cells and αCD40-IRES-CD19CAR T cells prepared in Example 2 were collected and divided into two portions, each of which was 1×10 ⁶ cells, washed twice with physiological saline, and 100 ul physiologically. The cells were resuspended in saline, one portion was added with 1 ug of CD19-biotin, and the other was added without incubation at 30 °C for 30 minutes. The saline was washed twice, and the cells were resuspended again with 100 ul of physiological saline, and 1 ul of streptomycin-PE antibody was added thereto, and incubated at 4 ° C for 30 minutes. The saline was washed twice, and the upper machine was tested, and only the secondary antibody was added as a control, and the results are shown in Fig. 2A.

2. ELISA assay for antibody expression levels of CD19CAR-αCD40T cells, CD19CAR-2A-αCD40T cells and αCD40-IRES-CD19CAR T cells prepared in Example 2.

1 Dilute the CD40 antigen to 0.5 ug/ml (5 ul + 1 ml coating solution) with a coating solution, and coat 100 ul/well of the enzyme-labeled reaction plate at 4 ° C overnight.

2 Wash 5 times with PBST for 3 minutes each time, pat dry with absorbent paper, 200 ul / well.

3 100 μl of blocking solution was added to each well and incubated at 37 ° C for 1 hour.

4 Wash 5 times with PBST for 3 minutes each time, pat dry with absorbent paper, 200 ul / well.

5 Add samples and standards, 100 ul / well, set up duplicate wells and control wells, incubate for 1 hour at 37 °C.

6 Wash 5 times with PBST for 3 minutes each time, pat dry with absorbent paper, 200 ul / well.

7 blocking solution was diluted with IgG F4HRP1: 30000, 100 ul / well, and incubated at 37 ° C for 45 minutes.

8 Wash 5 times with PBST for 3 minutes each time, pat dry with absorbent paper, 200 ul / well.

9 Add coloring solution TMB, 100 ul / well, and develop light at 37 ° C for 10-15 min.

10 The stop solution was added to stop the reaction, 50 ul / well.

The OD value was measured at 450 nm on a microplate reader, a standard curve was drawn, and the CD40 antibody concentration was calculated.

The result is shown in Figure 2B.

Example 4: Different plasmid ratio test of pNB328-CD19CAR and pS328-αCD40

The amount of pNB328-CD19CAR and pS328-αCD40 plasmids constructed in Example 1 were set to 1ug+7ug, 2ug+6ug, 3ug+5ug, 4ug+4ug, 5ug+3ug, 6ug+2ug, 7ug+1ug, respectively. The ratio of CAR T cells was constructed in the same manner as in Example 2. The positive rate of CAR T cells and the amount of antibody secretion were measured under the seven ratios (the same method as in Example 3), and the results are shown in Figs. 3A and 3B.

Example 5: Comparison of cytokine release by CD19CAR and CD19CAR-αCD40T cells under specific stimulation of CD19 antigen

The 96-well plate was coated with 2 ug/ml of CD19 antigen, coated overnight at 4° C., washed 3 times with PBS, and 1×10 ⁵ of CD19CAR and CD19CAR-αCD40T cells constructed in Example 2 and control Mock T cells were added and cultured. Cell supernatants were collected after 24 h. The cytokine secretion of these three T cells stimulated by CD19 antigen was detected by BD CBA Human Th1/Th2Cytokine Kit II. The specific steps are as follows:

(1) Mix human IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ to capture magnetic beads, vortex and mix to capture magnetic beads, add 50ul of each tube after mixing Capturing magnetic beads;

(2) Add 50 ul of Th1/Th2 cytokine standard (double dilution 5000pg/ml, 2500pg/ml, 1250pg/ml, 625pg/ml, 312.5pg/ml, 156pg/ml, 80pg/ml, 40pg/ml) , 20pg/ml, 0pg/ml) and 50ul of the sample to be tested (diluted by dilution 2 times);

(3) adding 50 ul of human Th1/Th2-II-PE detection antibody per tube;

(4) Incubate for 3 hours at room temperature in the dark;

(5) Add 1 ml of washing buffer to each tube, centrifuge at 200 for 5 min, and discard the supernatant;

(6) Resuspend the cells by adding 300 ul of washing buffer per tube, transfer to a flow tube, and measure the fluorescence value by flow cytometry.

The result is shown in Figure 4.

Example 6: Detection of proliferation of CD19CAR and CD19CAR-αCD40T cells

1. The CD19CAR T cells, CD19 CAR-αCD40 T cells and Mock T cells which were cultured on the 8th day were cultured in the same manner, and 3×10 ⁵ cells were taken and placed in a 12-well plate, and the culture volume was 1 ml.

2. Prepare a 96-well white opaque plate. From each of the three groups of cells, 100 μL of the cell-containing medium was added to the different wells, and the cell-free medium was taken as a blank control. 100 μL of CellTiter-Glo reagent was added to each well, mixed on an oscillator for 2 min, and incubated at room temperature for 10 min. The microplate reader read the Luc fluorescence value. The CellTiter-Glo Luminescent Cell Viability Assay kit used was purchased from Promega.

3. On the 9th, 10th, 11th, 12th, and 13th day of culture, samples were taken from the cells cultured in the 12-well plate every day, and detected according to the above steps. The cell proliferation curve was drawn according to the fluorescence value.

The results showed that CD19CAR-αCD40T cells had better proliferation effects than CD19CAR T cells. The specific results are shown in Figure 5.

Example 7: In vivo functional assay of CD19CAR T cells and CD19 CAR-αCD40 T cells.

Twelve NSG completely immunodeficient mice of 4-6 weeks old were used, with an average weight of 22-27 g, provided by Beijing Biotech Biotechnology Co., Ltd., and raised in SPF animal laboratory.

Human B cell lymphoma Raji-luc cells were cultured in vitro, and the cells were grown in logarithmic growth phase. After centrifugation, the cells were collected, resuspended in PBS, centrifuged at 3000 g for 2 minutes at room temperature, discarded, and resuspended in PBS and centrifuged. For cells, adjust the cell suspension concentration to 5 × 10 ⁷ /ml. The Raji-luc cells were inoculated subcutaneously into the right flank of the mouse, 0.1 ml/mouse. After about 10 days of inoculation, the tumor size was observed by a living imager, and NSG immunodeficient mice were randomly divided into 5 groups. The PBS group, Mock T group, CD19CAR T group, CD19CAR-αCD40-wt T, CD19CAR-αCD40T group, respectively, each group was injected with corresponding T cells (from Example 2) was 1 × 10 ⁷ / 100 ul, the route of administration For the tail vein injection. The living state of the mice was observed daily and the tumor changes of the mice were observed by a living imager every 7-8 days.

The result is shown in Figure 6.

Claims

A T cell that self-expresses a CD40 activating antibody and targets CD19; preferably, the T cell:

(1) a coding sequence comprising a chimeric antigen receptor recognizing CD19 and a coding sequence of a CD40 activating antibody; and/or

(2) expressing a chimeric antigen receptor and a CD40 activating antibody that recognize CD19;

Preferably, the expression cassette of the CD40 activating antibody and the expression cassette of the chimeric antigen receptor recognizing CD19 are integrated into the genome of the T cell.
The T cell according to claim 1, wherein the chimeric antigen receptor recognizing CD19 contains an optional signal peptide, an anti-CD19 single chain antibody, a hinge region, and a transmembrane region in order from N-terminus to C-terminus. Intracellular costimulatory signal domain and intracellular signal domain.
The T cell of claim 2, wherein the chimeric antigen receptor has one or more of the following characteristics:

The signal peptide is a CD8 signal peptide, a CD28 signal peptide or a CD4 signal peptide; preferably a CD8 signal peptide; preferably, the amino acid sequence of the CD8 signal peptide is amino acid residues 1-21 of SEQ ID NO: 1. Show

The amino acid sequence of the single chain antibody is shown as amino acid residues 22 to 263 of SEQ ID NO: 1;

The hinge region is selected from the group consisting of the extracellular hinge region of CD8, the IgG1 Fc CH2CH3 hinge region, the IgD hinge region, the CD28 extracellular hinge region, the IgG4 Fc CH2CH3 hinge region, and the extracellular hinge region of CD4; preferably the CD8 alpha hinge region or IgG4 CH2CH3 a hinge region; preferably, the amino acid sequence of the CD8 alpha hinge region is as shown in amino acid residues 264-308 of SEQ ID NO: 1;

The transmembrane region is selected from the group consisting of a CD28 transmembrane region, a CD8 transmembrane region, a CD3ζ transmembrane region, a CD134 transmembrane region, a CD137 transmembrane region, an ICOS transmembrane region, and a DAP10 transmembrane region; preferably a CD8 transmembrane region, preferably Its amino acid sequence is shown as amino acid residues 309-332 of SEQ ID NO:1;

The intracellular costimulatory signal domain is selected from the group consisting of CD28, CD134/OX40, CD137/4-1BB, lymphocyte-specific protein tyrosine kinase, inducible T cell costimulatory factor (ICOS), and intracellular DNAX activator protein 10. Domain; preferably, the intracellular costimulatory signal domain is the intracellular domain of CD137/4-1BB; preferably, the amino acid sequence of CD137/4-1BB is SEQ ID NO: 1 at positions 333-374 Amino acid residues are shown; and

The intracellular signal domain is a CD3 sputum intracellular signal domain or an FcεRI gamma intracellular signal domain; preferably a CD3 sputum intracellular signal domain, preferably the amino acid sequence of the CD3 sputum intracellular signal domain is SEQ ID NO: 1 at positions 375-486 Amino acid residues are shown.
The T cell according to claim 2 or 3, wherein the chimeric antigen receptor has one or more of the following characteristics:

The coding sequence of the signal peptide is shown as bases 1-63 of SEQ ID NO: 3;

The coding sequence of the anti-CD19 single-chain antibody is shown in nucleotide sequence 64-789 of SEQ ID NO: 3;

The coding sequence of the hinge region is shown in positions 790-924 of SEQ ID NO:3;

The coding sequence of the transmembrane region is shown as bases 925-996 of SEQ ID NO:3;

The coding sequence of the intracellular costimulatory signal domain is shown as bases 997-1122 of SEQ ID NO: 3;

The coding sequence for the intracellular signal domain is set forth in SEQ ID NO: 3, pp. 1123-1458.
The T cell according to claim 2, wherein the amino acid sequence of the chimeric antigen receptor is as shown in amino acid residues 22 to 486 of SEQ ID NO: 1, or as shown in SEQ ID NO: 1. Preferably, the coding sequence of the chimeric antigen receptor is as shown in SEQ ID NO: 3, bases 64-1458, or as shown in SEQ ID NO: 3.
The T cell according to any one of claims 1 to 5, wherein the CD40 activating antibody comprises an anti-CD40 single chain antibody and an IgG4 Fc; wherein the amino acid sequence of the IgG4 Fc is SEQ ID NO: 2 Shown at amino acid residues 269-497;

Preferably, the antibody light chain variable region amino acid sequence in the anti-CD40 single chain antibody is represented by amino acid residues 21 to 146 of SEQ ID NO: 2; preferably, the heavy chain in the anti-CD40 single chain antibody The variable region amino acid sequence is shown in amino acid sequence of positions 161-126 of SEQ ID NO: 2;

Preferably, the CD40 activating antibody further comprises a light chain signal peptide; preferably, the amino acid sequence of the light chain signal peptide is as shown in amino acid residues 1-20 of SEQ ID NO:2.
The T cell according to claim 6, wherein the amino acid sequence of the CD40 activating antibody is as shown in amino acid residues 21 to 497 of SEQ ID NO: 2, or as shown in SEQ ID NO: 2; Preferably, the coding sequence of the CD40 activating antibody is shown in the base sequence of positions 61-1491 of SEQ ID NO: 4, or as shown in SEQ ID NO: 4.
A composition or kit comprising:

(1) A vector comprising the expression cassette of the chimeric antigen receptor as defined in any one of claims 2 to 5, which is for integrating the expression cassette into the genome of the host cell;

(2) A vector comprising the expression cassette of the CD40 activating antibody as defined in any one of claims 6 to 7 for integration of the coding sequence into the genome of a host cell.
A pharmaceutical composition comprising the T cell of any one of claims 1-7.
Use of the T cell according to any one of claims 1 to 7 for the preparation of a medicament for treating or preventing malignancy; preferably, the malignant tumor is a malignant B cell lymphoma, including acute B lymphocytic leukemia, chronic B Lymphocytic leukemia, mantle cell lymphoma, non-Hodgkin's lymphoma, and multiple myeloma.